Companies
Is Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) Still Worth A Bite?
Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) previous close was $6.65 while the outstanding shares total 49.02M. The firm has a beta of 1.62. AGLE’s shares traded lower
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.